U.S. markets close in 2 hours 26 minutes
  • S&P 500

    4,199.52
    +77.05 (+1.87%)
     
  • Dow 30

    33,241.62
    +467.21 (+1.43%)
     
  • Nasdaq

    12,804.08
    +310.15 (+2.48%)
     
  • Russell 2000

    1,963.05
    +50.16 (+2.62%)
     
  • Crude Oil

    91.95
    +1.45 (+1.60%)
     
  • Gold

    1,814.00
    +1.70 (+0.09%)
     
  • Silver

    20.75
    +0.26 (+1.28%)
     
  • EUR/USD

    1.0323
    +0.0105 (+1.03%)
     
  • 10-Yr Bond

    2.7590
    -0.0380 (-1.36%)
     
  • GBP/USD

    1.2245
    +0.0169 (+1.40%)
     
  • USD/JPY

    132.3760
    -2.7400 (-2.03%)
     
  • BTC-USD

    23,918.40
    +790.82 (+3.42%)
     
  • CMC Crypto 200

    562.83
    +31.61 (+5.95%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

·3 min read
Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce
Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

Looking at the S&P 500 right now, you might be convinced the stock market is destined for doom in 2022.

The benchmark index rose nearly 27% last year. This year, it’s already down 20%. Plenty of stocks are deep into correction territory.

Yet JPMorgan’s global head of equity macro research, Dubravko Lakos, sees a major rebound on the horizon.

“People are basically positioned for a recession. Our base case is that this is not going to be a recession in the next 12 months,” Lakos told CNBC last month. “And we think from that angle the portfolios are wrong footed.”

Lakos reiterated a year-end price target of 4,900 for the S&P 500. Since the index sits at 3,820 today, his target implies a potential upside of around 28%.

If you’re aligned with Lakos and are looking ahead to a potential reversal, here’s three stocks JPMorgan finds particularly attractive right now.

Don’t miss

Smartsheet (SMAR)

This work-management platform helps companies implement, organize and automate their processes. Smartsheet says its application is used by more than 80% of Fortune 500 companies.

And business is growing. In the fiscal quarter ended April 30, revenue surged 44% year over year to $168.3 million, driven by a 44% increase in subscription revenue.

Notably, Smartsheet’s dollar-based net retention rate was a solid 133%.

But the stock is far from being a hot commodity. Year to date, shares are down a painful 55%. That could give contrarian investors something to think about.

Last month, JPMorgan analyst Pinjalim Bora reiterated an “overweight” rating on Smartsheet. While Bora also lowered his price target from $80 to $58, the new target is still 69% above where the stock sits today.

Microsoft (MSFT)

Tech stocks are getting dumped in this market downturn. Even mega-cap behemoths like Microsoft aren’t immune to the bearish sentiment.

The stock has tumbled 22% in 2022.

But business remains on the right track. In the March quarter, Microsoft’s revenue grew 18% year over year to $49.4 billion. Adjusted earnings came in at $2.22 per share, up 9% from the year-ago period.

The tech gorilla is also returning a massive amount of cash to investors. For the quarter, Microsoft’s dividends and share buybacks totaled $12.4 billion, representing a 25% increase year over year.

JPMorgan analyst Mark Murphy recently raised his price target on Microsoft to $320 while maintaining a “buy” rating. That implies a potential upside of 22%.

Eli Lilly (LLY)

This American pharmaceutical giant commands more than $300 billion in market cap, with products marketed in 120 countries around the world.

Unlike the other two names on this list, Eli Lilly is not a beaten-down stock.

In Q1, Eli Lilly delivered 15% revenue growth, driven by a 20% growth in volume. The company paid nearly $900 million in dividends and spent $1.5 billion on buybacks during the quarter.

Shares are actually up 19% so far in 2022, and JPMorgan expects the trend to continue.

On June 1, analyst Chris Schott reiterated an “overweight” rating on Eli Lilly while raising his price target from $340 to $355.

Considering that shares trade at around $325 apiece right now, the new price target implies a potential upside of 9%.

What to read next

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.